Merck Announces Presentation of New Findings for ZEPATIER ™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting®
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced results from multiple analyses atThe
Liver Meeting® 2016, which provide additional evidence
supporting the use of ZEPATIER ™ (elbasvir and grazoprevir) 50mg/100mg
tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or
GT4-infected patient populations, including those who receive opioid
agonist therapy (OAT), are infected with chronic HCV GT1b, use proton
pump inhibitors (PPIs) or ha ve moderate kidney disease.
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD The Liver Meeting ZEPATIER Source Type: news
More News: Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Proton Pump Inhibitors PPIs | Urology & Nephrology